Can creatine help during menopause? What the evidence says

Can creatine help during menopause? On a few narrow fronts, maybe. Muscle performance has the strongest backing by far. Cognition has one small trial worth paying attention to. But calling creatine a general menopause treatment goes well past what the data actually support.

Creatine is suddenly being sold as an answer to brain fog, weight gain and fading strength around menopause. The stronger case, so far, is narrower: creatine has decades of research in muscle performance, a smaller but growing body of work in bone and cognition, and exactly one trial aimed specifically at peri- and postmenopausal women. One trial, 36 women, eight weeks. That is the direct evidence, in full.

Falling estrogen can shift body composition, recovery, sleep and the way muscle responds to training — and that is what makes the distinction matter at midlife. Perimenopause is the transition years before the final menstrual period. Postmenopause begins after 12 consecutive months without one. A supplement that helps preserve strength or training response could matter in both phases. Whether creatine directly improves classic menopause symptoms — vasomotor symptoms, mood swings, sleep disruption — is much less clear.

A recent New York Times explainer helped push the question into the mainstream. The more useful place to look is the clinical literature, where the story is promising but still incomplete.

Why creatine entered the menopause conversation

Creatine is a compound stored mostly in muscle and, to a lesser degree, the brain, where it helps recycle adenosine triphosphate — ATP, the molecule cells use for quick energy. That is why it became popular in sports nutrition long before it entered wellness TikTok. The question now is whether that same energy-buffering role could help women navigating muscle loss, slower recovery and cognitive complaints around menopause.

In a 2025 review on creatine in women’s health, Smith-Ryan et al. (2025) argued that creatine is biologically plausible across the female lifespan. Then they wrote the sentence that sums up the field: “to date, there is no research directly evaluating the effects of creatine supplementation in perimenopausal women.” Plausibility is not proof. Menopause-specific outcomes remain under-studied, and the authors said so themselves.

What the menopause-specific trial actually found

The most relevant human paper is the 2026 CONCRET-MENOPA randomized trial. Korovljev et al. (2026) assigned 36 peri- and postmenopausal women to different interventions in a randomized controlled trial. Over eight weeks, the medium-dose group taking 1,500 mg/day of creatine hydrochloride improved reaction time and frontal brain creatine versus placebo (p < 0.01). All interventions were well tolerated, with no severe adverse effects.

The result matters because complaints loosely described as “brain fog” are common during the menopause transition. But here is what the trial did not measure: hot flashes, sleep quality, body weight, mood. The endpoints were cognitive — reaction time and brain creatine levels in a specific region. Thirty-six women over eight weeks, one form of creatine, one set of cognitive measures. The signal is real, but it answers a narrower question than the one most people are asking.

The stronger evidence is for muscle and bone, usually with exercise

The broader case for creatine at midlife comes from adjacent outcomes. In a 2-year randomized trial in 237 postmenopausal women, Chilibeck et al. (2023) paired resistance training with creatine monohydrate at 0.14 g/kg/day. The headline was not a dramatic standalone supplement effect — the study asked whether creatine could support training-related bone outcomes over time in women whose estrogen levels had already fallen.

Across the literature, the pattern is consistent. Creatine looks most useful as an adjunct to exercise, not as an all-purpose menopause supplement. A separate 2019 paper on creatine and resistance training in postmenopausal women by Candow et al. (2019) examined bone-health questions through that same lens. Someone hoping for a single powder that addresses every symptom of menopause will find a much narrower claim in the actual data. Someone focused on muscle, recovery and preserving function with age will find a more plausible use case.

There is a physiological reason for that narrower framing. Menopause is associated with declines in lean mass and changes in muscle protein turnover. Creatine’s best-established role is supporting high-intensity energy demands in muscle. Those mechanisms overlap with strength, training quality and physical function in a way they simply do not with vasomotor symptoms or mood.

Where the hype gets ahead of the data

Much of the current conversation bundles together several separate questions. Can creatine help maintain strength? Probably, especially when resistance training is already in the picture. The cognition question is more tentative — promising but early, with menopause-specific data limited to one small trial. And if someone asks whether creatine can treat menopause itself, the honest answer is that the data are not there yet.

The 2025 review is useful here because it separates sex-specific biology from wishful thinking. Women may respond differently to creatine across menstruation, pregnancy and menopause, but the paper also makes clear that the menopause literature has holes. The supplement industry, podcast circuit and social feeds rarely pause on that point.

Dose is another place to tread carefully. The human studies in this area did not all use the same form or amount. The 2026 trial used creatine hydrochloride at 1,500 mg/day. The longer postmenopausal exercise trial used creatine monohydrate at 0.14 g/kg/day. Those are study protocols, not a recommendation. Anyone considering creatine should consult a doctor before starting any supplement, especially if they have kidney disease, take multiple medications or are trying to solve symptoms that could have another medical cause.

What to watch next

The next useful studies will be larger trials that separate outcomes instead of collapsing them into a vague promise of “menopause support.” Researchers need to test whether creatine changes muscle performance, daily function, sleep, mood, body composition or cognitive symptoms in perimenopausal women specifically, and over longer periods than eight weeks. They also need to compare forms and doses directly.

For now, creatine is plausible for a few menopause-related goals and overhyped for many others. The best support is indirect and exercise-linked. The 2026 trial offers an intriguing cognitive signal — not a verdict but a reason to keep watching the research. Anyone looking at creatine through a menopause lens should treat it as a targeted performance and physiology question, not a universal fix.

References

1. Korovljev D, et al. CONCRET-MENOPA: creatine hydrochloride and ethyl ester RCT. PubMed. 2026. https://pubmed.ncbi.nlm.nih.gov/40854087/
2. Chilibeck PD, et al. A 2-yr randomized controlled trial on creatine supplementation during exercise for postmenopausal bone health. PubMed Central. 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10487398/
3. Candow DG, et al. Effects of creatine and resistance training on bone health in postmenopausal women. PubMed. 2019. https://pubmed.ncbi.nlm.nih.gov/31257405/
4. Smith-Ryan AE, et al. Creatine in women’s health: bridging the gap from menstruation through pregnancy to menopause. PubMed Central. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12086928/